Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Hypertension in HIV: Management and Treatment.

Ucciferri C, Falasca K, Vecchiet J.

AIDS Rev. 2017 May 23;19(2). [Epub ahead of print]

PMID:
28534890
2.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group.; AIFA team..

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

PMID:
28497758
3.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group..

Infection. 2017 May 5. doi: 10.1007/s15010-017-1018-z. [Epub ahead of print]

PMID:
28477212
4.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group..

Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9.

PMID:
27956268
5.

Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related.

Falasca K, Reale M, Ucciferri C, Di Nicola M, Di Martino G, D'Angelo C, Coladonato S, Vecchiet J.

AIDS Res Hum Retroviruses. 2017 Mar;33(3):246-253. doi: 10.1089/AID.2016.0138. Epub 2016 Oct 12.

PMID:
27615271
6.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group..

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5.

PMID:
27272727
7.

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy.

Ucciferri C, Falasca K, Vignale F, Di Nicola M, Vecchiet J.

Braz J Infect Dis. 2016 Jul-Aug;20(4):401-2. doi: 10.1016/j.bjid.2016.02.002. Epub 2016 Mar 8. No abstract available.

8.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group..

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849.

9.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
10.

Antiretroviral therapy management and rationalisation of available resources.

Cirioni O, Castelletti S, Ucciferri C, Falasca K, Orsetti E, Mazzocato S, Valeriani C, Di Campli FM, Barchiesi F, Vecchiet J, Giacometti A.

Infez Med. 2015 Dec;23(4):330-5.

11.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group..

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

12.

Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.

Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group..

Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. doi: 10.1016/j.cmi.2015.10.026. Epub 2015 Nov 10.

13.

Long term effect of telmisartan in HIV-positive male patients with high blood pressure.

Ucciferri C, Falasca K, Vignale F, Di Nicola M, Vecchiet J.

Braz J Infect Dis. 2015 Nov-Dec;19(6):668-9. doi: 10.1016/j.bjid.2015.08.012. Epub 2015 Oct 23. No abstract available.

14.

High prevalence of human papillomavirus type 58 in HIV infected men who have sex with men: A preliminary report in Central Italy.

Sammarco ML, Ucciferri C, Tamburro M, Falasca K, Ripabelli G, Vecchiet J.

J Med Virol. 2016 May;88(5):911-4. doi: 10.1002/jmv.24406. Epub 2015 Oct 28.

PMID:
26467111
15.

Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?

Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, Celesia BM, Parruti G, Babudieri S, Bonfanti P, Falasca K, Vichi F, De Socio GV, Salomoni E, Di Biagio A, Quirino T.

Eur J Gastroenterol Hepatol. 2016 Jan;28(1):37-41. doi: 10.1097/MEG.0000000000000483.

PMID:
26460621
16.

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study.

Falasca K, Vecchiet J, Ucciferri C, Di Nicola M, D'Angelo C, Reale M.

Nutrients. 2015 Sep 28;7(10):8335-47. doi: 10.3390/nu7105396.

17.

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group..

Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6.

PMID:
26424550
18.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group..

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
19.

Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.

Cingolani A, Zona S, Girardi E, Cozzi-Lepri A, Monno L, Quiros Roldan E, Guaraldi G, Antinori A, D'Arminio Monforte A, Marcotullio S; Community-Oriented Study Group of the Icona Foundation Study Group..

HIV Med. 2015 Aug;16(7):412-20. doi: 10.1111/hiv.12226. Epub 2015 May 11.

20.

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.

Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group..

PLoS One. 2015 May 1;10(5):e0124252. doi: 10.1371/journal.pone.0124252. eCollection 2015.

Supplemental Content

Loading ...
Support Center